The divergent effect of RU 486 on adrenal function in the dog is related to differences in its pharmacokinetics.
This study has evaluated the relationship between the antiglucocorticoid effect of RU 486 and its pharmacokinetics in seven female mongrel dogs (weight 21-30 kg), all of which had appropriate responses to insulin-induced hypoglycemia and metyrapone. They were given RU 486 (50 mg.kg-1.d-1) for ten days. Three dogs (responders) demonstrated increased secretion of ACTH and cortisol which reached a maximum at the termination of RU 486 administration and returned to baseline by days 22 and 18, respectively. The remaining four dogs (non-responders) showed only transient non-sustained increases in ACTH and cortisol. Serum concentrations of RU 486 and its monodemethylated and di-demethylated (but not its hydroxylated) metabolites were significantly higher in the responder dogs. The ratios of the hydroxylated metabolite to RU 486 and its demethylated derivatives were higher in the non-responders, whereas the ratio of the di-demethylated to monodemethylated compound was higher in the responders. Since variations in the hydroxylation and reductive catabolism of steroids have been well documented in different strains of a species, it is possible that the differences in levels of RU 486 and its metabolites in the two groups are accounted for by variations in RU 486 metabolism. In the responder group the metabolism of RU 486 is directed to demethylation, and in the non-responder group to hydroxylation. Thus, differences in pharmacokinetics of RU 486 in the two groups of dogs may explain the variable biological response to this antiglucocorticoid.
Spitz
I M
IM
Center for Biomedical Research, Population Council, New York, NY.
Heikinheimo
O
O
Wade
C E
CE
D000284:Administration, Oral; D000302:Adrenal Cortex / Q000187:drug effects* / Q000378:metabolism; D000324:Adrenocorticotropic Hormone / Q000097:blood; D000704:Analysis of Variance; D000818:Animals; D001798:Blood Proteins / Q000187:drug effects; D001835:Body Weight / Q000187:drug effects; D004285:Dogs; D005260:Female; D006854:Hydrocortisone / Q000097:blood; D007003:Hypoglycemia / Q000139:chemically induced / Q000378:metabolism; D007030:Hypothalamo-Hypophyseal System / Q000187:drug effects; D007328:Insulin / Q000378:metabolism; D008797:Metyrapone / Q000494:pharmacology; D015735:Mifepristone / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000494:pharmacology*; D010913:Pituitary-Adrenal System / Q000187:drug effects; D013997:Time Factors
D001798:Blood Proteins; D007328:Insulin; D015735:Mifepristone; D000324:Adrenocorticotropic Hormone; D006854:Hydrocortisone; D008797:Metyrapone